A previous study showed use of SGLT2 inhibitors tended to decrease higher blood urate levels in younger than older age groups.29 Studies reported that blood urate–lowering effects were not apparent in patients with CKD,30,31 possibly explaining no associations between SGLT2 inhibitors and gout incidence (HR, 1.01; 95% CI, 0.86-1.19) in patients with CKD in our study. Here, SLC5A2 is linked to chronic kidney disease.